Treatment for primary biliary cholangitis

Abstract

The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.

1 . A method of treating primary biliary cholangitis, comprising administering orally to a human in need thereof, a therapeutically effective amount saroglitazar magnesium salt to treat the primary biliary cholangitis; wherein saroglitazar is represented by: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The method of  claim 1 , wherein an amount from about 0.5 mg to about 5 mg saroglitazar is administered. 
     
     
         3 . The method of  claim 1 , wherein saroglitazar magnesium salt is the sole therapeutic agent for treating the primary biliary cholangitis. 
     
     
         4 . The method of  claim 1 , wherein administering occurs for at least 16 weeks.